Form 8-K - Current report:
SEC Accession No. 0000950170-22-014457
Filing Date
2022-08-04
Accepted
2022-08-04 07:03:21
Documents
14
Period of Report
2022-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K omga-20220804.htm   iXBRL 8-K 54767
2 EX-99.1 omga-ex99_1.htm EX-99.1 238562
3 GRAPHIC img220583725_0.jpg GRAPHIC 6092
  Complete submission text file 0000950170-22-014457.txt   437363

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT omga-20220804_lab.xml EX-101.LAB 14010
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT omga-20220804_pre.xml EX-101.PRE 10297
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT omga-20220804.xsd EX-101.SCH 2484
8 EXTRACTED XBRL INSTANCE DOCUMENT omga-20220804_htm.xml XML 4920
Mailing Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140
Business Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 221134589
SIC: 2836 Biological Products, (No Diagnostic Substances)